Takeda Pharmaceutical (TAK) Long-Term Investments (2017 - 2026)
Takeda Pharmaceutical (TAK) posted quarterly Long-Term Investments of $63.2 million for Q2 2026, down 8.02% year-over-year from $68.7 million in Q2 2025, and up 12.73% quarter-over-quarter from $56.1 million in Q1 2026.
Takeda Pharmaceutical (TAK) Long-Term Investments (2017 - 2026) Analysis & Trends
Takeda Pharmaceutical's Long-Term Investments history runs 10 years deep, the most recent figure standing at $63.2 million for Q2 2026.
- In Q2 2026, Long-Term Investments fell 8.02% year-over-year to $63.2 million; the TTM figure through Jun 2026 stood at $63.2 million (down 8.02% YoY), while the FY2026 annual figure was $58.4 million, down 97.47% from the prior year.
- Long-Term Investments for Q2 2026 stood at $63.2 million, up from $56.1 million in the prior quarter.
- The five-year high for Long-Term Investments was $2.3 billion in Q1 2025, with the low at $56.1 million in Q1 2026.
- The 5-year median for Long-Term Investments is $683.7 million (2022), against an average of $715.5 million.
- The sharpest annual moves came in 2023 and 2026: Long-Term Investments jumped 154.42% in 2023, then plunged 97.56% in 2026.
- Takeda Pharmaceutical's Long-Term Investments stood at $668.4 million in 2022, then grew by 4.57% to $698.9 million in 2023, then slumped by 88.06% to $83.5 million in 2024, then fell by 20.69% to $66.2 million in 2025, then retreated by 4.5% to $63.2 million in 2026.
- Business Quant data shows TAK's Long-Term Investments at $63.2 million in Q2 2026, $56.1 million in Q1 2026, and $66.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | 92.58 Mn |
| 2 | Teva Pharmaceutical Industries | 43.41 Bn | 39.75 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.83 Bn | 30.15 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.97 Bn | 5.10 Bn | 63.23 Mn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 1.14 Bn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | 149.10 Mn |
| 8 | Elanco Animal Health | 11.93 Bn | 11.40 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | 60.00 Mn |
| 10 | Alkermes | 8.20 Bn | 7.55 Bn | 397.90 Mn | 35.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 63.23 Mn |
| Mar 31, 2026 | 56.09 Mn |
| Dec 31, 2025 | 66.21 Mn |
| Sep 30, 2025 | 60.53 Mn |
| Jun 30, 2025 | 68.74 Mn |
| Mar 31, 2025 | 2.30 Bn |
| Dec 31, 2024 | 83.48 Mn |
| Sep 30, 2024 | 104.77 Mn |
| Jun 30, 2024 | 563.30 Mn |
| Mar 31, 2024 | 2.30 Bn |
| Dec 31, 2023 | 698.93 Mn |
| Sep 30, 2023 | 713.99 Mn |
| Jun 30, 2023 | 732.76 Mn |
| Mar 31, 2023 | 2.11 Bn |
| Dec 31, 2022 | 668.38 Mn |
| Sep 30, 2022 | 701.41 Mn |
| Jun 30, 2022 | 750.74 Mn |
| Mar 31, 2022 | 831.05 Mn |
| Dec 31, 2021 | 919.37 Mn |
| Sep 30, 2021 | 1.05 Bn |